- Previous Close
24.67 - Open
24.52 - Bid 24.50 x --
- Ask 24.89 x --
- Day's Range
24.37 - 24.95 - 52 Week Range
9.13 - 25.80 - Volume
351,264 - Avg. Volume
971,112 - Market Cap (intraday)
8.238B - Beta (5Y Monthly) 2.38
- PE Ratio (TTM)
164.07 - EPS (TTM)
0.15 - Earnings Date Feb 20, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.62
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
telixpharma.comRecent News: TLX.AX
View MorePerformance Overview: TLX.AX
Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLX.AX
View MoreValuation Measures
Market Cap
8.24B
Enterprise Value
8.24B
Trailing P/E
167.79
Forward P/E
77.52
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.92
Price/Book (mrq)
20.67
Enterprise Value/Revenue
12.96
Enterprise Value/EBITDA
113.13
Financial Highlights
Profitability and Income Statement
Profit Margin
7.62%
Return on Assets (ttm)
7.97%
Return on Equity (ttm)
20.49%
Revenue (ttm)
645.68M
Net Income Avi to Common (ttm)
49.19M
Diluted EPS (ttm)
0.15
Balance Sheet and Cash Flow
Total Cash (mrq)
118.84M
Total Debt/Equity (mrq)
5.48%
Levered Free Cash Flow (ttm)
105.93M